Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Idarucizumab Humanized Recombinant Human Monoclonal Antibody
FIGURE: 1 / 1
Idarucizumab Humanized Antibody (MA5-41998) in SDS-PAGE
SDS-PAGE analysis of the recombinant Pradaxa (Dabigatran Etexilate Mesylate) dabigatran etexilate mesylate protein expressed in CHO cells using a Idarucizumab biosimilar monoclonal antibody (Product # MA5-41998). R denotes the lane was run under reducing conditions. NR denotes the lane was run under non-reducing conditions.
Product Details
MA5-41998
Product Specifications
Species Reactivity
Chemical
Host/Isotype
Human
/ IgG1, F(ab), kappa
Expression System
CHO cells
Class
Recombinant Monoclonal
Type
Antibody
Immunogen
Pradaxa (Dabigatran Etexilate Mesylate) dabigatran etexilate mesylate
Conjugate
Form
Liquid
Concentration
2.53 mg/mL
Purification
Protein L
Storage buffer
30mM histidine, pH 5.8, with 10% sucrose, 0.06% Tween 80
Contains
no preservative
Storage conditions
-20°C, Avoid Freeze/Thaw Cycles
Shipping conditions
Ambient (domestic); Wet ice (international)
RRID
AB_2911141
Product Specific Information
Endotoxin level < 0.01EU/µg by LAL method
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Target Information
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, especially when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin use, etc.). Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations. Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of dabigatran. Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support